Meeting report of the third Heidelberg myeloma workshop: current status and developments in diagnosis and therapy of multiple myeloma

2011 ◽  
Vol 138 (1) ◽  
pp. 173-178 ◽  
Author(s):  
Jens Hillengaß ◽  
Kai Neben ◽  
Hartmut Goldschmidt
Keyword(s):  
Multiple Myeloma ◽  
Current Status ◽  
Meeting Report ◽  
The Third ◽  
Diagnosis And Therapy

Current status and developments in diagnosis and therapy of multiple myeloma

2009 ◽  
Vol 136 (1) ◽  
pp. 151-155 ◽  
Author(s):  
Jens Hillengass ◽  
Kai Neben ◽  
Hartmut Goldschmidt
Keyword(s):  
Multiple Myeloma ◽  
Current Status ◽  
Diagnosis And Therapy

scholarly journals Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

Leukemia ◽  
2015 ◽  
Vol 30 (3) ◽  
pp. 526-535 ◽  
Author(s):  
S Lonial ◽  
B Durie ◽  
A Palumbo ◽  
J San-Miguel
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibodies ◽  
Current Status ◽  
Future Perspectives

Providing Data for Educational Policy in an International Context: The Third International Mathematics and Science Study (TIMSS)

1997 ◽  
Vol 13 (1) ◽  
pp. 49-58 ◽  
Author(s):  
Albert E. Beaton ◽  
Michael O. Martin ◽  
Ina V.S. Mullis
Keyword(s):  
International Perspective ◽  
Current Status ◽  
Informational Needs ◽  
Science Study ◽  
Educational Decisions ◽  
Comparative Performance ◽  
Policy Makers ◽  
International Context ◽  
The Third ◽  
Mathematics And Science

Policy-makers in many nations of the world are involved in educational reforms. In order to make effective educational decisions for the 21st century, policy-makers need information of a wide variety of kinds, for example, comparative performance data and curriculum information from other nations. National assessments can be valuable, but international surveys provide a broader base of information and allow countries to view their current status and planning within an international perspective. The purpose of this paper is to describe the goals of the Third International Mathematics and Science Study and the steps being followed to insure that the results from the study will meet the diverse informational needs of policy-makers.

scholarly journals Minimal residual disease in multiple myeloma: current status

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Hong Ding ◽  
Juan Xu ◽  
Zhimei Lin ◽  
Jingcao Huang ◽  
Fangfang Wang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Expression Profiles ◽  
Cell Cancer ◽  
Gene Expression Profiles ◽  
Current Status ◽  
Cytogenetic Aberration ◽  
The Status ◽  
Minimal Residual

AbstractMultiple myeloma (MM) is a treatable plasma cell cancer with no cure. Clinical evidence shows that the status of minimal residual disease (MRD) after treatment is an independent prognostic factor of MM. MRD indicates the depth of post-therapeutic remission. In this review article, we outlined the major clinical trials that have determined the prognostic value of MRD in MM. We also reviewed different methods that were used for MM MRD assessment. Most important, we reviewed our current understanding of MM MRD biology. MRD studies strongly indicate that MRD is not a uniform declination of whole MM tumor population. Rather, MM MRD exhibits unique signatures of cytogenetic aberration and gene expression profiles, unlike those of MM cells before therapy. Diagnostic high-risk MM and low-risk MM exhibited a diversity of MRD features. Clonal evaluation may occur at the MRD stage in MM. The dynamics from the diagnostic MM to MRD correlate with the disease prognosis. Lastly, on the aspect of omics, we performed data-based analysis to address the biological features underlying the course of diagnostic-to-MRD MM. To summarize, the MRD stage of disease represents a critical step in MM pathogenesis and progression. Demonstration of MM MRD biology should help us to deal with the curative difficulties.

Sign in / Sign up

Export Citation Format

Share Document